Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Jan

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

HCC LLM Advice and Treatment Concordance

Can a Genetic Variant Affect the Efficacy of Abiraterone

Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence

What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?